Donate

Kedrion Announces Return to Normal Supply Levels of Koāte

May 12, 2017

Kedrion Biopharma announced a return to normal supply levels of Koāte in the 1000 vial size and a series of large-scale improvements to their overall operations following a temporary period of limited availability of product. Click here to read the full contents of letter provided by Kedrion Biopharma regarding this matter.  

Kedrion Announces Voluntary, Temporary Hold on Koate-DVI

July 6, 2016

Kedrion Biopharma provided the following announcement today: Koate®-DVI Summer Supply Statement Kedrion Biopharma has placed a voluntary, temporary hold on further shipments of Koate-DVI until approximately the September timeframe. The company is working to restore supplies of Koate-DVI as soon as possible so that it can be made available to patients who require it. This is being […]

FDA Approves Needle-Free Transfer Device for Hemophilia A Product

March 31, 2016

Note: The following in an edited press release from Kedrion Biopharma. The original release can be read in its entirety here. Kedrion Biopharma has gained approval from the U.S. Food and Drug Administration to package Koāte® Double Viral Inactivation (DVI) Antihemophilic Factor (human) with Mix2Vial™, a needle-free transfer device. The new packaging is designed to offer hemophilia […]

Kedrion Announces Safer Manufacture Process for Koate Antihemophilic Factor

April 6, 2015

Note: This is an edited version of a Kedrion press release. To read the full release, click here.  ____________________ Kedrion Biopharma proudly announced that Koate® Double Viral Inactivation (DVI) Antihemophilic Factor (human) is now being manufactured using a process that further enhances the safety and purity of that product. Koate-DVI is used in the treatment […]


Sign up for E-mails, Dateline Magazine, and other ways to stay connected.